TrialInternational journal of chronic obstructive pulmonary disease

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.

Kai Michael Beeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.